SCHEMBL5651307

SCHEMBL5651307

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccc(C(F)(F)F)cc2)c1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.47
MAPT P10636 9/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
KDM4E B2RXH2 3/20 0.44
HSP90AA1 P07900 1/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
ALDH1A1 P00352 3/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
POLB P06746 2/20 0.40
GPR55 Q9Y2T6 1/20 0.40
ADORA1 P30542 1/20 0.39
TRPM8 Q7Z2W7 2/20 0.39
CYP3A4 P08684 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
HPGD P15428 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5654243 0.96 MAPT (0.46) DHODHMAPTMEN1KMT2AKDM4E
SCHEMBL5650136 0.90 MAPT (0.51) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5650443 0.90 MAPT (0.50) DHODHMAPTMEN1KMT2AKDM4E
SCHEMBL5652521 0.90 MAPT (0.41) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5652293 0.89 MAPT (0.44) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5650867 0.89 MAPT (0.47) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5652595 0.88 MAPT (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5652764 0.88 MAPT (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5647395 0.87 MAPT (0.50) DHODHMAPTMEN1KMT2AKDM4E
SCHEMBL5654426 0.87 ALDH1A1 (0.50) DHODHMAPTMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 DHODH 3102/4885MAPT 3795/4885MEN1 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.